Sun Pharmaceutical Industries' (NSE:SUNPHARMA, BOM:524715) consolidated net profit declined to 22.8 billion Indian rupees in the fiscal first quarter ended June 30, against 28.4 billion rupees a year ago.
Earnings per share contracted to 9.5 rupees compared with 11.8 rupees a year earlier, the pharmaceutical company said in a filing to the Indian stock exchanges on Thursday.
Revenue from operations in fiscal Q1, however, grew to 138.5 billion rupees from 126.5 billion rupees a year ago.
The company's shares were down 1% in recent trade.
免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。